Search Results - "HAY, J. W."

The US economic and social costs of Alzheimer's disease revisited by Ernst, R L, Hay, J W

“…OBJECTIVEs. An earlier paper estimated the per-case and national incidence costs of Alzheimer's disease for 1983. This paper updates the estimates of costs per…”
Get full text

Using Pharmacoeconomics to Value Pharmacotherapy by Hay, JW

“…Pharmacotherapeutic decisions are increasingly constrained in all clinical settings by the costs of drug treatment and medical care. Some biotech therapies…”
Get full text

Evaluation of Strategies for Use of Acellular Pertussis Vaccine in Adolescents and Adults: A Cost-Benefit Analysis by Purdy, Kenneth W., Hay, Joel W., Botteman, Marc F., Ward, Joel I.

“…Pertussis is increasingly recognized as a source of infection in adults who then commonly infect young children. Immunity to illness caused by Bordetella…”
Get full text

Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom by Botteman, M. F., Hay, J. W., Luo, M. P., Curry, A. S., Wong, R. L., van Hout, B. A.

“…Objectives. This study evaluated the cost effectiveness of adalimumab vs conventional therapy in patients with active ankylosing spondylitis (AS). Methods. The…”
Get full text

The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States by Messali, Andrew, Hay, Joel W, Villacorta, Reginald

“…The objective of this work was to determine the cost-effectiveness of temozolomide compared with that of radiotherapy alone in the adjuvant treatment of newly…”
Get full text

Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors by HAY, J. W., ZHOU, Z. Y.

“…To construct a cost‐minimization model comparing activated prothrombin complex concentrates (APCC) vs. recombinant factor VIIa (rFVIIa) in haemophilia patients…”
Get full text

Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors by Hay, J. W., Chaugule, S. C., Young, G.

“…Summary Published studies suggest that bypass therapy assay testing can be used to predict treatment response and dosing requirements for haemophilia patients…”
Get full text

Economic research on Alzheimer disease: a review of the literature by Ernst, R L, Hay, J W

“…The present review discusses the economic research to date on Alzheimer disease (AD). It focuses on estimates of the costs of AD and on economic evaluations of…”
Get more information

Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease by Ashraf, Talat, Hay, Joel W., Pitt, Bertram, Wittels, Ellison, Crouse, John, Davidson, Michael, Furberg, Curt D., Radican, Larry

“…This study analyzed the cost-effectiveness of pravastatin in secondary prevention of coronary artery disease (CAD). The projected risk model in 445 male…”
Get full text

Inflammatory bowel disease: costs-of-illness by Hay, J W, Hay, A R

“…We have evaluated the economic costs to society for the two major types of inflammatory bowel disease, Crohn's disease and ulcerative colitis, using a medical…”
Get more information

Economic burden of haematological adverse effects in cancer patients: a systematic review by Liou, S Y, Stephens, J M, Carpiuc, K T, Feng, W, Botteman, M F, Hay, J W

“…Patients receiving cancer treatments commonly experience haematological adverse effects (AEs) related to chemotherapy or molecularly targeted therapies, which…”
Get full text

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease by Hay, J W, Yu, W M, Ashraf, T

“…Cardiovascular disease is the leading cause of death and the leading source of healthcare expenditure in the US and most other industrialised countries…”
Get full text

The economic costs of Alzheimer's disease by Hay, J W, Ernst, R L

“…This paper estimates the economic costs of Alzheimer's Disease to individuals and to society, based on review of published Alzheimer's Disease-related…”
Get full text

Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors by HAY, J. W., ZHOU, Z.-Y.

Get full text

Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease by Hay, J W, Robin, E D

“…Alpha 1-antitrypsin (AAT) replacement therapy is an expensive intervention ($20,000-$30,000 per patient annually) which may slow or arrest the progression of…”
Get full text

An Evaluation of the Cost-Effectiveness of Reslizumab in Poorly Controlled Eosinophilic Asthma by Lam, J, Hay, JW, Salcedo, J, Kenyon, NJ

Get full text

Management Of Spinal Cord Injury-Associated Neuropathic Pain With Pregabalin Is Cost-Effective Over Gabapentin by Patel, NV, Hay, JW

Get full text

The costs and social burdens of Alzheimer disease: what can and should be done? by Hay, J W, Sano, M, Whitehouse, P J

Get more information

The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services by McCombs, JS, Liu, G, Shi, J, Feng, W, Cody, M, Parker, JP, Nichol, MB, Hay, JW, Johnson, KA, Groshen, SL, Nye, MT

“…The impacts of three alternative models of pharmacist consultation on the use and cost of health care services were studied. Two studies were conducted…”
Get full text

An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction by Hay, Joel W., Wittels, Ellison H., Gotto, Antonio M.

“…The costs and benefits of cholesterol lowering in the primary prevention of coronary artery disease (CAD) were considered using lifetime lovastatin therapy as…”
Get full text